Myositis News and Research

RSS
Myositis is inflammation of your skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis. The diseases dermatomyositis and polymyositis both involve myositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Both diseases are usually treated with prednisone, a steroid medicine, and sometimes other medicines.
Weekly doses of steroids help hasten recovery in muscle injuries

Weekly doses of steroids help hasten recovery in muscle injuries

Virulence of bacterial infections dependent on presence of cytotoxins, study reports

Virulence of bacterial infections dependent on presence of cytotoxins, study reports

Anti-TNF therapy offers new hope to JDM patients

Anti-TNF therapy offers new hope to JDM patients

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Former all-American wrestler speaks about his personal battle with chronic muscle disease

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera collaborates with TMA to advance new potential treatment approach for myositis

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

New antibody could boost strength, muscle mass in patients with cancer and other diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

Cancer triggers scleroderma, shows evidence

Cancer triggers scleroderma, shows evidence

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

Researchers create specific tests to detect cancer biomarkers in patients with dermatomyositis

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

DYNC1H1 genetic mutation contributes to SMA-LED

DYNC1H1 genetic mutation contributes to SMA-LED